IRVINE, Calif. March 5, 2024— Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, announced the appointment of Mike Mathias as the company’s Chief Commercial Officer, effective immediately. With a distinguished 30-year career in leading commercial organizations within the cardiovascular arena, Mike brings a wealth of experience and a proven track record of success to Endologix.
Matt Thompson, MD, President, and CEO of Endologix, expressed his opinion on Mike’s appointment: “We are delighted to bring such an experienced and successful leader into Endologix. Mike is uniquely qualified to lead our global commercial team and continue the strategic development of our commercial plans. His extensive experience and success in launching pioneering therapies in the medical device industry make him an invaluable asset to our senior leadership team. We believe that with Mike’s leadership, our global sales, business development, and marketing teams will continue to thrive.”
In response to his new role, Mike Mathias shared, “Joining Endologix at such a critical juncture is an honor. I am excited to apply my experience to innovate and join the leadership team of a company that stands at the forefront of interventional vascular therapies. Together, we will work to enhance our commercial strategy, ensuring success for our commercial teams and the organization as a whole.”
With over three decades of leadership in commercial organizations within the medical device industry, Mike has contributed to the advancement of Endovascular Aneurysm Repair (EVAR) and therapies for Peripheral Vascular Disease. His tenure included pivotal roles, notably leading the U.S. launch of the LimFlow System. Prior to joining LimFlow, Inc, he spent 20 years in various commercial leadership roles at Medtronic. He led Medtronic’s $1.2 billion Heart Valve Therapies U.S commercial operations, launching Transcatheter Aortic Valve Replacement (TAVR). Mike’s successful tenure at both Medtronic and LimFlow is distinguished by the launch of groundbreaking therapies, demonstrating his exceptional strategic planning, team leadership, and capability for market expansion. He earned his B.S. in Arabic and French Studies from the U.S. Military Academy at West Point, further enriching his leadership skills with an MBA from the University of Minnesota.
About Endologix
Endologix LLC is a California-based, global medical device company dedicated to improving patients’ lives by providing innovative therapies for the interventional treatment of vascular disease. Endologix’s therapeutic portfolio includes a variety of products in various stages of development that are designed to treat diseases that currently have clinically relevant unmet needs. Endologix’s commercial products, including the AFX®2 Endovascular AAA System, ALTO® Abdominal Stent Graft System, and the DETOURTM System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. Endologix is wholly owned by Deerfield Management, an investment management firm committed to advancing healthcare through investment, information, and philanthropy. The company has offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, California. To learn more about Endologix, please visit https://www.endologix.com/.
Media Contact:
Sandy Prietto
949-595-7240
sprietto@endologix.com
